Actively Recruiting

Phase 3
Age: 18Years +
All Genders
Healthy Volunteers
ID05456503

Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Disease Using the PET Ligand [18F]-PI-2620

Led by University of Pennsylvania · Updated on 2025-11-04

72

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

U

University of Pennsylvania

Lead Sponsor

N

National Institutes of Health (NIH)

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are comparing brain scans using the [18F]-PI-2620 tracer in people with frontotemporal lobar degeneration (FTLD), non-amnestic Alzheimer's disease (naAD), and healthy adults. This study builds upon a larger observational research project (UNICORN) that collects brain imaging, clinical assessments, and genetic data to better understand neurodegenerative diseases. Participants include various groups diagnosed by neurologists, aiming to see how tau protein accumulates in different conditions. Participants undergo a baseline PET/CT brain scan with the [18F]-PI-2620 tracer. If funding allows, some may return for additional scans 12 to 24 months apart to monitor changes over time. Seven groups are studied, including healthy adults, different types of FTLD, and Alzheimer's subtypes. Each participant will have at least one PET scan to assess tau accumulation in the brain. During the study, participants continue their involvement in the UNICORN observational study, which includes periodic MRI scans and neuropsychological testing. Researchers measure brain tau levels using PET scan results and track cognitive and functional abilities. Safety is monitored, and participants provide informed consent. The study plans to collect data over about six years, with ongoing assessments of brain imaging and clinical status.

CONDITIONS

Brief Title

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older and currently enrolled in the UNICORN study
  • Cognitively and neurologically normal adults or clinically diagnosed with specific neurodegenerative conditions including non-amnestic or amnestic Alzheimer's disease, frontotemporal lobar degeneration (FTLD) with tau or TDP-43 pathology, or genetic forms of FTLD
  • Not clinically depressed based on Geriatric Depression Scale score  6 or clinical evaluation
  • Have a study partner and legally authorized representative (LAR) if applicable
  • For genetic groups, must have a confirmed mutation in the MAPT, GRN, or C9orf72 genes or be an asymptomatic carrier
  • Diagnosed by trained clinicians according to established criteria for each group
Not Eligible

You will not qualify if you...

  • Presence of medical or psychiatric conditions that could compromise safety or study participation
  • Evidence of major stroke or brain mass on MRI within 6 months prior to enrollment
  • Unable to tolerate or contraindicated for imaging procedures
  • Pregnant or breastfeeding females at the time of PET/CT scan
  • History of significant alcohol or substance abuse or dependence
  • Currently enrolled in a clinical trial for a disease-modifying treatment targeting their neurodegenerative condition

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Screening and enrollment documentation is completed through the parent UNICORN study.

Diagnostic Evaluation

Duration - Single visit

Participants undergo a baseline PET/CT brain imaging scan using the [18F]-PI-2620 tracer to assess tau accumulation.

1 visit (in-person) for the PET/CT scan

Long-term Monitoring

Duration - Up to 6 years depending on funding and scheduling

Participants may return for one or more follow-up PET/CT brain scans between 12 and 24 months after the previous scan to monitor changes in tau accumulation over time.

1 to multiple visits (in-person) scheduled at least 12 months apart

Trial Site Locations

Total: 1 location

1

Perelman Center for Advance Medicine

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

Loading map...

Research Team

D

David J Irwin, MD

J

Jeffrey S Phillips, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

DIAGNOSTIC

Number of Arms

7

Similar Trials

Comparison of Cardiac [18F]-MFBG PET Versus [123I]-MIBG SPEC...

Parkinson Disease

Actively Recruiting

2 locations

An Open-label, Non-randomized, Multi-center Pivotal Phase 3 ...

Alzheimer Disease

Actively Recruiting

25 locations

A Feasibility Study of Green Activity Program for People Liv...

Mild Cognitive Impairment

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here